Daniel J. Lebovic
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
Papers in
- Hematology 24
- Multiple Myeloma Research and Treatments 22
-
- Lymphoma Diagnosis and Treatment 10
- Co-authors
- Andrzej J. Jakubowiak (11 shared papers)Mark Stefan Kaminski (11 shared papers)Kent A. Griffith (11 shared papers)Keith E Stockerl-Goldstein (5 shared papers)Sundar Jagannath (6 shared papers)Dominik Dytfeld (6 shared papers)Ravi Vij (6 shared papers)Tara B. Anderson (5 shared papers)
- Journals
- Blood (25 papers)British Journal of Haematology (2 papers)Clinical Cancer Research (2 papers)JAMA Network Open (1 paper)Cancer Cell (1 paper)
- Partner nations
- United StatesPolandSpain
In The Last Decade
Daniel J. Lebovic
41 papers receiving 2.9k citations
Daniel J. Lebovic's Hit Papers
Peers
Comparison fields: 5 of 77
- Hematology 1.4k
- Oncology 1.2k
- Pathology and Forensic Medicine 775
- Genetics 356
- Immunology 530
Countries citing papers authored by Daniel J. Lebovic
This map shows the geographic impact of Daniel J. Lebovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel J. Lebovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel J. Lebovic more than expected).
Fields of papers citing papers by Daniel J. Lebovic
This network shows the impact of papers produced by Daniel J. Lebovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel J. Lebovic. The network helps show where Daniel J. Lebovic may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel J. Lebovic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study Hit paper breakdown → | 2016 | 875 |
| 2 | Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy Hit paper breakdown → | 2014 | 819 |
| 3 | 2012 | 374 | |
| 4 | 2015 | 175 | |
| 5 | 2014 | 150 | |
| 6 | 2014 | 105 | |
| 7 | 2016 | 78 | |
| 8 | 2011 | 36 | |
| 9 | 2018 | 33 | |
| 10 | 2018 | 32 | |
| 11 | 2013 | 29 | |
| 12 | 2014 | 29 | |
| 13 | 2013 | 28 | |
| 14 | 2011 | 21 | |
| 15 | 2011 | 14 | |
| 16 | 2013 | 14 | |
| 17 | 2012 | 14 | |
| 18 | 2014 | 14 | |
| 19 | 2010 | 13 | |
| 20 | 2010 | 13 |
About Daniel J. Lebovic
Daniel J. Lebovic is a scholar working on Hematology, Pathology and Forensic Medicine, Oncology, Genetics and Molecular Biology, having authored 43 papers that have together received 2.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (22 papers), Protein Degradation and Inhibitors (12 papers), Lymphoma Diagnosis and Treatment (10 papers), Chronic Lymphocytic Leukemia Research (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Peptidase Inhibition and Analysis (5 papers), HER2/EGFR in Cancer Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Hematology (1.4k citations), Oncology (1.2k citations), Pathology and Forensic Medicine (775 citations), Genetics (356 citations) and Immunology (530 citations). Daniel J. Lebovic has collaborated with scholars based in United States, Poland and Spain. Frequent co-authors include Andrzej J. Jakubowiak, Mark Stefan Kaminski, Kent A. Griffith, Keith E Stockerl-Goldstein, Sundar Jagannath, Dominik Dytfeld, Ravi Vij, Tara B. Anderson, Kristen Detweiler‐Short and David H. Vesole. Their work appears in journals such as Blood, British Journal of Haematology, Clinical Cancer Research, JAMA Network Open and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.